half-life comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Batch-to-batch variation is normal |
| Solubility class | Soluble in water, buffer, and dimethyl sulfoxide | Aqueous solubility is moderate |
| Typical storage temperature | Minus 20 degrees Celsius dry, 2 to 8 degrees Celsius reconstituted | Avoid repeated freeze-thaw |
| Common analytical method | Reverse-phase HPLC with electrospray mass detection | Used for purity and mass confirmation |
| Common synonyms | GLP-1 analog, semaglutide peptide | Wording varies across suppliers |
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
=== "Central pillar" cave structure === In the typical "central pillar" design, pilgrims can circumambulate around a central column incorporating a niche for a statue of the Buddha, which is a representation of the stupa. The so-called "central pillar" which appears on a plan is actually not a pillar at all but only the rock at the back of the cave, into which was bored a circular corridor allowing for circumambulation. A large vaulted chamber is located in front of the "central pillar" column and a smaller rear chamber behind with two tunnel-like corridors on the sides linking these spaces. In the front chamber, a three-dimensional image of Buddha would have been housed in a large niche serving as the focus of the interior, however, none of these sculptures have survived at Kizil. The rear chamber may feature the parinirvana scene in the form of a mural or large sculpture, and in some cases, a combination of both. The "central pillar" layout is possibly related to the structural design of Kara Tepe in northern Bactria. The program of the paintings in the "central pillar" caves generally follows a fixed arrangement: the walls of the main cella show sermons of the Buddha, the ceiling has rhomboid vignettes alluding to Jatakas, the central niche has the scene of the Indrasala Cave. The back room or corridor has scenes related to the Parinirvana, and finally the painting over the exit is related to the Tusita Heaven and the future Buddha Maitreya.
The DLD homodimer functions as the E3 component of the pyruvate, α-ketoglutarate, α-adipate and branched-chain amino acid-dehydrogenase complexes and the glycine cleavage system, all in the mitochondrial matrix. In these complexes, DLD converts dihydrolipoic acid and NAD+ into lipoic acid and NADH. DLD also has diaphorase activity, being able to catalyze the oxidation of NADH to NAD+ by using different electron acceptors such as O2, labile ferric iron, nitric oxide, and ubiquinone. DLD is thought to have a pro-oxidant role by reducing oxygen to a superoxide or ferric to ferrous iron, which then catalyzes production of hydroxyl radicals. Diaphorase activity of DLD may have an antioxidant role through its ability to scavenge nitric oxide and to reduce ubiquinone to ubiquinol. The dihyrolipamide dehydrogenase gene is known to have multiple splice variants.
AS9100 Revision C (2009), Quality Management System – Requirements for Aviation, Space and Defense Organizations The update of AS9100 from revision B to C is largely to address the following question: "Our supplier is repeatedly late on delivery and failing to meet our requirements, how is it possible that they still have their AS9100 certificate?" That is, the AS9100C changes are driven by repeated delivery of non-conforming product and repeated late delivery by organizations that held AS9100A/B certifications. Those organizations had documented controls that conformed to the standard, however, there were insufficient processes in place to assure effectiveness of those controls. The response in this AS9100 revision is to elevate the requirements for Risk Management and to make Risk Management an integrated theme throughout the standard. A major challenge to AS9100B-compliant organizations was the new AS9100 auditing standards defined in AS9101 Revision D, which eliminates the clause-based compliance checklist and requires organizations to provide evidence of effectiveness of their systems and processes. Summary of changes between AS9100B and AS9100C:
As a result, a reactor operating at constant power has a fixed steady-state equilibrium concentration, but when lowering reactor power, the 135Xe concentration can increase enough to effectively shut down the reactor. Without enough neutrons to offset their absorption by 135Xe, nor to burn the built-up xenon, the reactor has to be kept in shutdown state for 1–2 days until enough of the 135Xe decays. 135Xe beta-decays with half-life of 9.2 hours to 135Cs; a poisoned core will spontaneously recover after several half-lives. After about 3 days of shutdown, the core can be assumed to be free of 135Xe, without it introducing errors into the reactivity calculations. The inability of the reactor to be restarted in such state is called xenon precluded start up or dropping into an iodine pit; the duration of this situation is known as xenon dead time, poison outage, or iodine pit depth. Due to the risk of such situations, in the early Soviet nuclear industry, many servicing operations were performed on running reactors, as downtimes longer than an hour led to xenon buildup that could keep the reactor offline for significant time, lower the production of 239Pu, required for nuclear weapons, and would lead to investigations and punishment of the reactor operators.
== Description == The cap is 1.5–4 centimetres (1⁄2–1+1⁄2 in) across, dry, at first hemispheric, expanding to campanulate or convex, with an incurved margin when young. Young caps start out light brown and fade to off-white or light gray at maturity, sometimes with yellowish or brownish tones. Often developing cracks in dry weather, slightly hygrophanous, turning greenish or blue where damaged. The gills are broadly adnate to adnexed, close, starting out gray and turning black as the spores mature. The gill faces have a mottled appearance and the edges are white. The spore print is black. The stipe is 6–12 cm long by 2 to 4 mm thick, equal to slightly enlarged at the base, pruinose, colored like the cap, staining somewhat blue where bruised. The taste and odor are farinaceous.
Sources: en.wikipedia.org
== Atomistic Fracture Mechanics == Atomistic Fracture Mechanics (AFM) is a relatively new field that studies the behavior and properties of materials at the atomic scale when subjected to fracture. It integrates concepts from fracture mechanics with atomistic simulations to understand how cracks initiate, propagate, and interact with the microstructure of materials. By using techniques like Molecular Dynamics (MD) simulations, AFM can provide insights into the fundamental mechanisms of crack formation and growth, the role of atomic bonds, and the influence of material defects and impurities on fracture behavior.
=== Electrical neuromodulation === Several forms of electrical neuromodulation, including transcutaneous electrical nerve stimulation (TENS) and transcranial direct current stimulation (tDCS), have been used to treat fibromyalgia. In general, they help reduce pain and depression and improve functioning. Transcutaneous electrical nerve stimulation (TENS) is the delivery of pulsed electrical currents to the skin to stimulate peripheral nerves. TENS is widely used to treat pain and is considered to be a low-cost, safe, and self-administered treatment. As such, it is commonly recommended by clinicians to people suffering from pain. In 2019, an overview of eight Cochrane reviews was conducted, covering 51 TENS-related randomized controlled trials. The review concluded that the quality of the available evidence was insufficient to make any recommendations. A 2020 review concluded that transcutaneous electrical nerve stimulation may diminish pain in the short term, but there was uncertainty about the relevance of the results. Preliminary findings suggest that electrically stimulating the vagus nerve through an implanted device can potentially reduce fibromyalgia symptoms. However, there may be adverse reactions to the procedure. Noninvasive brain stimulation includes methods such as transcranial direct current stimulation and high-frequency repetitive transcranial magnetic stimulation (TMS). Both methods have been found to improve pain scores in neuropathic pain and fibromyalgia.
As the surface of the sensor shears through the liquid, energy is lost due to its viscosity. This dissipated energy is then measured and converted into a viscosity reading. A higher viscosity causes a greater loss of energy. Extensional viscosity can be measured with various rheometers that apply extensional stress. Volume viscosity can be measured with an acoustic rheometer. Apparent viscosity is a calculation derived from tests performed on drilling fluid used in oil or gas well development. These calculations and tests help engineers develop and maintain the properties of the drilling fluid to the specifications required. Nanoviscosity (viscosity sensed by nanoprobes) can be measured by fluorescence correlation spectroscopy.
== Calculation == As noted before, DIAAS considers the digestibility of individual essential amino acids (EAAs). The amounts of each amino acid in the test food and in the digested mixture at the end of the small intestine is subtracted to give the absorbed amount of each EAA ai. The value is divided by the total amount of protein in the test food to give the milligrams of each EAA absorbed for each gram of the protein Ai. One then looks up the desired reference pattern, which gives the amount of an EAA in 1 gram of the "reference protein" Ri. For each EAA, the "reference ratio" Ai/Ri is calculated. The final DIAAS is 100% times the lowest reference ratio. Amino acid digestibility is preferably scored using humans. If humans are not available, determination in growing pigs or growing rats are acceptable. For measurement in humans, a minimally invasive dual-tracer method has been developed for the DIAAS method.
Shortly afterwards, the US VII Corps, in full strength and spearheaded by the 2nd Armored Cavalry Regiment, launched an armored attack into Iraq early on 24 February, just to the west of Kuwait, surprising Iraqi forces. Simultaneously, the US XVIII Airborne Corps launched a sweeping "left-hook" attack across southern Iraq's largely undefended desert, led by the US 3rd Armored Cavalry Regiment and the 24th Infantry Division (Mechanized). This movement's left flank was protected by the French Division Daguet. The 101st Airborne Division conducted a combat air assault into enemy territory. The 101st Airborne Division had struck 249 km (155 mi) behind enemy lines. It was the deepest air assault operation in history. Approximately 400 helicopters transported 2,000 soldiers into Iraq where they destroyed Iraqi columns trying to flee westward and prevented the escape of Iraqi forces. The 101st Airborne Division travelled a further 80 to 100 km (50 to 60 mi) into Iraq. By nightfall, the 101st cut off Highway 8 which was a vital supply line running between Basra and the Iraqi forces. The 101st had lost 16 soldiers in action during the 100-hour war and captured thousands of enemy prisoners of war. The French force quickly overcame Iraq's 45th Infantry Division, suffering light casualties and taking a large number of prisoners, and took up blocking positions to prevent an Iraqi counterattack on the coalition's flank. The movement's right flank was protected by the United Kingdom's 1st Armoured Division.
Sources: en.wikipedia.org
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.
Deamidated and oxidized forms are the most frequently reported impurities. Truncated peptide fragments from incomplete synthesis also appear at low levels. Their relative abundance grows with time, heat exposure, and unfavorable pH.
Retention time matching on a validated column provides strong circumstantial evidence. It does not distinguish compounds with similar hydrophobicity. Mass measurement or peptide mapping is needed for unambiguous identification.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.